Amendments to Bylaws (Form 8-K)

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the "Board") of Intellia Therapeutics, Inc. (the "Company"), the Board adopted amendments to the Company's Third Amended and Restated By-laws.Under the Fourth Amended and Restated By-laws,which are effective April 7, 2026 (the "Amended By-laws"),the Company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder's timely notice of a nomination or proposal, and requiring the Company to notify the shareholder of any facially apparent deficiencies in a timely notice. In addition, the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.

A copy of the Amended By-laws isfiled as Exhibit 3.1 to this Current Report on Form 8-K and isincorporated herein by reference, and the foregoing summary is qualified in its entirety by reference to the full text of the Amended By-laws.